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Abstract 
Objective: HIV infection may result in stressful situations such as disclosure to others 
and could be a mediator between seropositivity status and psychiatric illness, 
depression or anxiety. Several results have shown that anxiolytic use (mainly 
benzodiazepines) is highly prevalent in HIV-infected individuals, but few studies have 
highlighted to what extent this use could be associated with HIV disclosure. Design: A 
national cross-sectional survey representative of people living with HIV and AIDS in 
France enrolled 2932 individuals in 102 French HIV hospital departments. Methods: 
Face-to-face interviews and self-administered questions collected information about 
patients’ experience with HIV and HIV care, including use of psychotropic drugs, social 
support, stigma and disclosure of HIV status. We identified factors associated with 
regular BDZ use (i.e. more than once a week) using a weighted logistic regression model. 
Results: Regular BDZ use and anxiety symptoms were reported by 16% and 29% of the 
patients respectively. After multiple adjustment for known correlates of BDZ use and 
anxiety symptoms, individuals who had disclosed their HIV status to relatives or friends 
were found to be more likely (OR[95%CI]= 1.78 [1.02-3.09]) to regularly use BDZ. 
Conclusions: These results show both to what extent disclosure to others continues to 
be a stressful step in the course of HIV infection and that disclosure is something which 
could be identified by BDZ use. They also highlight the need for appropriate case 
management and psychiatric care to help patients manage the consequences of 
disclosure. 
Words: 239 
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Introduction 
 
Mood and anxiety disorders are known to be highly prevalent in HIV infected individuals 
(Bing, et al., 2001; Silverman, 1993) and are of great concern because of their impact on 
HIV care effectiveness (Whetten, Reif, Whetten, & Murphy-McMillan, 2008). Depressive 
symptoms have been widely recognized as a determinant of non-adherence to ART 
(Starace, et al., 2002) and are found to impair virological suppression in patients 
receiving ART (Villes, et al., 2007). Anxiety symptoms have been investigated to a lesser 
extent (e.g. (Chander, Himelhoch, & Moore, 2006)) despite evidence about their 
negative impact on health outcomes in the HIV positive population (Campos, 
Guimaraes, & Remien, 2010; Roux, et al., 2009). Anxiety symptoms are core symptoms 
of different disorders, including generalized anxiety disorder, social phobia, 
agoraphobia, panic attacks, obsessive-compulsive disorder and post-traumatic stress 
disorder (Roy-Byrne, et al., 2010). They are also present for those with depression, often 
being even more prominent than depressive symptoms, and therefore giving rise to the 
diagnosis of “anxious depression” (Nelson, 2008). However, anxiety symptoms may also 
occur in reaction to stressful situations, as is the case for example during the course of 
HIV infection, especially with regard to  its psycho-social burden (Gonzalez, Solomon, 
Zvolensky, & Miller, 2009), e.g. reduced social support, financial insecurity and 
stigmatization  (Bravo, Edwards, Rollnick, & Elwyn, 2010; Michels & Marzuk, 1993). This 
may also be the case following HIV disclosure to relatives and friends (Golub, Tomassilli, 
& Parsons, 2009). While some studies have shown that living with the HIV secret may be 
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more emotionally harmful than the stigma resulting from disclosure, this latter may 
nonetheless be seen as a stressful event (Gielen, O'Campo, Faden, & Eke, 1997). The 
study conducted by Niccolai et al. on disclosure of HIV serostatus to sex partners 
showed that non-disclosure is often underestimated and is motivated by the fear of 
negative consequences (Niccolai, King, D'Entremont, & Pritchett, 2006). Our hypothesis 
is based on the theory described by Hatzenbuehler that HIV serostatus disclosure may 
increase exposure to stress resulting from stigma (Hatzenbuehler, 2009). This stigma 
related stress may result in anxiety-like reactions such as the taking of anxiolytics. A 
recent article shows that in France benzodiazepines are widely abused (Pradel, Delga, 
Rouby, Micallef, & Lapeyre-Mestre, 2010) and prescribed despite their poor benefit/risk 
ratio for most anxiety disorders (Pelissolo, et al., 2007) and for major depressive 
disorders (Davidson, 2010). As previously seen, anxiety symptoms feature in several 
diagnoses of anxiety or depressive disorders. Their prevalence is high during chronic 
illnesses (Filipcic, et al., 2007), especially among HIV-infected patients, and they are 
often determined by the specific medical condition together with environmental factors 
and psychological traits. Assessing the use of BDZ would therefore appear to be of 
clinical relevance as it may be an indicator of exposure to stressful events, such as 
discrimination, which are not always easy to disclose to one’s physician. The Vespa 
survey, a national cross-sectional study, conducted in France in a representative sample 
of HIV infected individuals gave us the opportunity to study correlates, and more 
particularly the impact of HIV status disclosure on regular BDZ use.  
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Methods 
 
Study design 
The ANRS-EN12-VESPA study was supported by the French National Agency of AIDS and 
Hepatitis Research (ANRS) and consisted of a national cross-sectional survey conducted 
in 2003 among a random sample of 4,963 HIV-infected patients recruited in 102 French 
hospital departments delivering HIV care. The sample was stratified according to each 
department’s geographic location and HIV caseload (Peretti-Watel, et al., 2005). Eligible 
subjects were French speaking outpatients diagnosed with HIV-infection for at least 6 
months, aged 18 or older, and living in France for at least 6 months. Each patient 
interview lasted on average 40 minutes. When the interview ended, if the patient had 
been deemed eligible for study participation, he/she was consulted by the physician. 
Patients who agreed to participate signed a letter of informed consent and answered a 
face-to-face questionnaire administered by a trained interviewer with the CAPI system 
(Computer Assisted Personal Interview). As patients who attended outpatient clinics 
were overrepresented more frequently, the sample was weighted by the inverse of 
patients’ annual number of visits in the clinic (since the probability of being asked to 
participate was proportional to this number). 
 
Study population 
Among the eligible patients in the Vespa study, 2932 agreed to participate, 1767 refused 
and 264 were not solicited as their physician considered that their physical or 
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psychological conditions were not compatible with participation in the survey. Non-
respondents were not significantly different from respondents in terms of gender, age, 
viral load or CD4 lymphocyte count. Of the 2932 participants, 667 (22.7%) did not 
answer the Hospital Anxiety and Depression scale (HADS) questions, included in the 
study. We therefore restricted our analysis to 2265 (77.3%) respondents. After 
conducting a sensitivity analysis between respondents (i.e. those who answered the 
HADS questions) and non-respondents, no significant differences were observed 
between both groups in terms of age, undetectable viral load, HIV clinical stage, ART 
receipt and BDZ use. 
 
Data collection 
The questionnaire comprised approximately 400 questions in 10 modules, but only a 
subset of these has been used in the present article. One section of the questionnaire 
collected socio-demographic information about gender, age, origin (i.e. being born 
outside of France or not), living in a couple or not, educational level, employment and 
various life events including experience of discrimination, incarceration, prostitution, 
suicide attempts and HIV status disclosure to someone including relatives, friends or 
others.    
Another section of the questionnaire focused on HIV medical information such as time 
since HIV diagnosis, receiving ART or not, self-reported side-effects and finally, 
transmission group (injecting drug use (IDU), men who have sex with men (MSM), and 
heterosexual contact). The prevalence of anxiety and depression were assessed using 
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the HADS, which is a 14-item self-rating instrument (7 items relating to anxiety and 7 to 
depression) on a 4-point Likert scale, assessing individuals’ experiences over the 
previous week. For each subscale (anxiety or depression), the score is the sum of the 
respective items (ranging from 0-21). In clinical practice, individuals are considered as 
follows: not clinically depressed/anxious if their total score for each HADS subscale lies 
between 0 and 7, borderline depressed/anxious for scores between 8 and 10, and 
clinically depressed/anxious for scores of 11 or more. In our analysis, we chose to use 
these three categories to define anxiety symptoms (Thomas, et al., 2005). 
 
Information regarding alcohol abuse was collected using the CAGE questionnaire based 
on four items (Malet, Schwan, Boussiron, Aublet-Cuvelier, & Llorca, 2005). Consumption 
of psychotropic medications (antidepressants, hypnotics and anxiolytics such as 
benzodiazepines) was reported by patients and documented by recording the frequency 
of consumption during the previous 4 weeks, in a medical or non-medical context. The 
different frequencies of use were: “never (no use)”, “less than once a week”, “once a 
week”, “several times a week”, and “daily or almost daily”. These possibilities were 
applied to a list of benzodiazepines (alprazolam, bromazepam, clobazam, clorazepate, 
diazepam, flunitrazepam, loprazolam, oxazepam, prazepam). For this study, we 
classified those whose frequency was “once a week”, “several times on a week” and 
“daily or almost daily” as regular consumers of benzodiazepines and moderate/non-
consumers for those whose frequency was “never” or “less than once a week”. The 
outcome variable was then dichotomized according to these two groups. 
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A dichotomized indicator of HIV disclosure (Yes or No) was constructed using data from 
a set of questions about HIV disclosure. The main question asked was the following: 
“Have you told anyone about your infection since becoming aware of it and when?”. For 
each relative (e.g. father, mother, sibling, other relative) and friend, participants had to 
choose one answer from the following possibilities:  
(1)“Yes, immediately when I was informed of my infection”, (2)“Yes, during hospital 
stay”, (3)“Yes, at treatment initiation”, (4)“Yes, on another occasion”, (5)“No, she/he 
doesn’t know”, (6)“No, but she/he discovered it from someone else”, (7)“I don’t know if 
she/he knows”, (8)“Non-applicable”, (9)“ I refuse to answer”. Participants who chose 
answer (1), (2), (3), (4) or (6), were considered to have disclosed their HIV serostatus. 
When a patient answered (5), (7) or (8), he/she was considered to have declared non-
disclosure. Answer (9) was considered as missing data. 
 
Statistical Analysis 
Risk factors and other explanatory variables were screened for inclusion in the model by 
testing each independently for a significant association with regular benzodiazepine use, 
using weighted univariate logistic regression. Variables which achieved a liberal 
significance level of /P/ ≤ 0.20 in the univariate analysis were included in the 
multivariate model. The final multivariate model was built using a backward elimination 
approach based on the log-likelihood ratio (p</ ≤ 0.05). A receiver operating 
characteristic (ROC) curve was used to assess the logistic regression model’s ability to 
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accurately distinguish individuals who regularly used benzodiazepines from all the 
others.  
The area under the ROC curve (AUC) provides a measure of discrimination (Hosmer & 
Lemeshow, 2000):  when 0.7 ≤ AUC < 0.8 the discrimination power is considered to be 
satisfactory. Data management and statistical analyses were performed using SPSS 
v15.0 software (SPSS Inc., Chicago, IL, USA). 
 
Results 
 
Socio-demographic and behavioral characteristics on 2265 patients are presented in 
Table 1. The whole sample comprised 604 (27%) women and median [IQR] age was 
41[36; 47] years. Nearly one third of the patients had a secondary school certificate and 
more than half (59%) had a job.  Migrants represented 366 individuals, corresponding to 
16% of the sample. 
With regard to negative life events, 39% patients reported suffering from discrimination, 
one fifth (22%) of the patients reported attempting suicide and nearly one patient in 
eight (11%) had never disclosed their HIV status to anyone.  
With respect to medical characteristics, 762 (32%) patients had been HIV-infected by 
heterosexual contact, 1003 (47%) by homosexual contact and 377 (17%) by intravenous 
drug use. The median time since HIV diagnosis was 9[5; 14] years. Most individuals 
(80%) were receiving ART and nearly one quarter (24%) reported perceiving side-effects 
at the time of the study. Twenty-two percent of the patients (495) were classified with 
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HIV clinical stage C and 68% had an undetectable viral load. Anxiety and depressive 
symptoms (corresponding to a HADS score greater than 11) were found respectively in 
667 (29%) patients and 215 patients (10%). The Cronbach’s alpha coefficient was 0.80 
for anxiety and 0.82 for depression. 
Alcohol abuse was identified in 301 (13%) individuals using the CAGE score. With regard 
to the use of psychotropics during the previous month, 356 (16%) reported regular 
benzodiazepine consumption while 215 (9%) reported antidepressant use during the 
previous 4 weeks. 
  
Univariate analysis (Table 1) showed that several variables were determinants of regular 
BDZ use. In regard to socio-demographic factors, individuals with no employment or no 
secondary school certificate were more likely to use BDZ regularly. Not surprisingly, this 
was also found for individuals who presented certain characteristics related to drug use 
or psychiatric illnesses (IDU HIV transmission group, alcohol abuse, antidepressants use, 
anxiety symptoms). Many variables relating to negative life events, such as 
discrimination or suicide attempts, were found to be significantly associated with the 
outcome. With respect to HIV-related factors, we found that individuals who had 
disclosed their HIV serostatus, those not receiving ART, those with HIV clinical stage C 
and those who perceived self-reported symptoms were more likely to use BDZ. 
 
In multivariate analysis (Table 2), one interesting result is that HIV status disclosure 
remained associated with regular BDZ use (OR [95%CI]=1.78 [1.02-3.09]). To confirm our 
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hypothesis, we adjusted for some eligible factors such as older age, living in a couple, 
diagnosis of HIV clinical stage C, reporting anxiety symptoms (OR [95%CI]=6.02[4.39-
8.26]) or a history of suicide attempts and finally belonging to the IDU or MSM HIV 
transmission group. It is important to note that patients who had depressive symptoms 
were not more likely to be regular BDZ users. Another interesting factor associated with 
regular BDZ c nsumption was that of being a “migrant” (i.e. being born outside of 
France). A bivariate analysis showed that migrants were less likely to disclose their HIV 
status. We also evaluated the discriminatory performance of the final statistical model; 
the area under the ROC Curve was 0.74 with a 95% confidence interval [0.72-0.77], 
which is an acceptable discrimination according to Hosmer and Lemeshow. 
 
Discussion 
 
This study provides novel results about the prevalence and the correlates of regular 
benzodiazepine (BDZ) use in a representative sample of HIV-infected individuals in 
France.  
First, we identified known correlates deserving further investigation in terms of 
improving the clinical evaluation of BDZ use, something which is desirable for several 
reasons. To begin with, its regular use is known to induce dependence and cognitive 
impairment (Barker, Greenwood, Jackson, & Crowe, 2004). Although access to 
anxiolytics was found to be associated with higher adherence to ART for women in this 
same VESPA survey (Roux, et al., 2009), other studies have highlighted that cognitive 
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impairment is a determinant of non-adherence to ART (Carballo, et al., 2004; Hinkin, et 
al., 2004). In addition, as many other findings have already shown, BDZ abuse is 
responsible for many side effects (Chouinard, 2004) and should be taken into account 
when considering drug-drug interaction in ART treated patients (Greenblatt, von 
Moltke, Daily, Harmatz, & Shader, 1999).  
Second, HIV disclosure to relatives or friends was significantly associated with regular 
BDZ use (although this association was not as strong as that found for the other 
variables). As for a series of other stressful situations, this association has consistently 
been found in the literature (Niccolai, et al., 2006). We found that most of the patients 
(89%) had already disclosed their HIV status to a relative or a friend confirming that HIV-
infected individuals need to cope with the disclosure of their infection to someone 
during the course of HIV disease (Feskanich, et al., 2002). It is known that HIV status 
disclosure is underestimated and consequently deserves investigation, particularly in 
clinical practice. The findings in this paper might well encourage physicians to 
investigate more thoroughly what psycho-social factors lie behind the use of BDZ. As it is 
very difficult for an HIV physician to directly tackle exposure to stigma during face-to-
face interviews, discussing the patient’s use of anxiolytics (more frequently prescribed 
by primary care physicians) could provide an indication of the level of difficulty patients 
face when coping with stressful situations. Moreover, speaking about anxiolytics’ 
effectiveness could provide an opportunity for the patient to talk about the context of 
social situations which generate anxiety symptoms. Therefore, providing patients with 
both social and psychological follow-up may help achieve early detection and better 
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management of stressful situations. Indeed, the fact that disclosure of HIV status to 
relatives or friends was associated with regular BDZ use supports the conclusion of 
Petrak et al. suggesting that reasons for non-disclosure include the desire to protect 
others from distress and fear of discrimination (Petrak, Doyle, Smith, Skinner, & Hedge, 
2001). It is also known that willingness to disclose is negatively associated with HIV-
related stigma (Yang, Li, et al., 2006) which may be a cause of anxiety (Golub, Tomassilli, 
& Parsons, 2009). Although patients need to disclose their HIV-positive status in order to 
receive specific advice, emotional support and information, disclosure of one’s HIV 
infection may nonetheless be considered as a traumatic event at the origin for anxiety 
symptoms (Siegel, Lekas, & Schrimshaw, 2005).  
 
As in other studies, we found that certain socio-demographic characteristics, such as 
older age, unemployment and not living in a couple were significantly associated with 
the outcome. As expected, patients who were affected by anxiety symptoms were more 
likely to regularly use BDZ (Demyttenaere, et al., 2008). Some previous findings have 
already shown that older HIV infected patients experience a greater number of 
psychiatric comorbidities, including anxiety symptoms and sleep disorders (Kilbourne, 
Justice, Rabeneck, Rodriguez-Barradas, & Weissman, 2001).  
In addition, our results suggest that certain indicators of positive social functioning, such 
as having employment and living in a couple, are associated with less frequent BDZ use. 
This is consistent with findings from many other studies which have suggested that 
receiving social support is associated with reduced emotional distress and consequently 
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reduced BZD consumption (Serovich, Kimberly, Mosack, & Lewis, 2001). Conversely, 
having less social contact has been found to be a high risk factor for anxiety in elderly 
patients (Majercsik & Haller, 2004). Moreover, alcohol abuse and BDZ dependence are 
known to be intimately correlated (Ashton, 2005) and early BDZ treatment may bring 
about alcohol dependence (Martijena, Lacerra, Bustos, & Molina, 2001).  
With regard t  medical characteristics, individuals with clinical stage C (i.e. who had 
experienced clinical progression to AIDS) were more likely to regularly use BDZ. This is 
perhaps because, in general, experience of clinical progression is accompanied by stress 
(Kalichman, Difonzo, Austin, Luke, & Rompa, 2002) and the difficulty to hide one’s HIV 
status. 
Migrants were less likely to regularly use BDZ and were also more likely to conceal their 
HIV status. These results are consistent with those in previous studies showing that fear 
of discrimination and stigma is very prevalent in the migrant community (Fakoya, 
Reynolds, Caswell, & Shiripinda, 2008).  
On the contrary, we found that individuals belonging to MSM or IDU HIV transmission 
groups were more likely to report regular benzodiazepine use. Indeed, these groups 
often face and perceive more discrimination and stigmatization than heterosexual HIV-
infected individuals (Herek, Capitanio, & Widaman, 2003). 
 
Benzodiazepine use has been found to be associated with a history of suicide attempts 
even after adjustment for anxiety and depressive symptoms. Even though no 
association was found between benzodiazepine use and depressive symptoms in this 
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study, a history of suicide attempts may be considered as an indicator of previous 
psychiatric comorbidities, such as major depression (Horesh, Sever, & Apter, 2003) or 
negative life events and discrimination (Preau, Bouhnik, Peretti-Watel, Obadia, & Spire, 
2008).  
 
Some limitati ns of the study have to be acknowledged. Although the HADS is a 
common and convenient instrument to measure depression and anxiety symptoms in 
patients with both somatic and mental problems in the general population (Mykletun, 
Stordal, & Dahl, 2001), it is not recognized as being the most relevant system to use for 
those suffering from major depression (Bunevicius, Peceliuniene, Mickuviene, Valius, & 
Bunevicius, 2007). That is why the correct diagnosis of major depression, which is 
imperative in clinical practice, needs a more adapted tool in the research context. 
Moreover, it is difficult to find the causality between disclosure and BDZ use and this 
issue needs to be investigated more thoroughly. Despite this weakness, one of the 
major strengths of this study is that it is based on a large representative sample of HIV 
infected individuals - through homosexual or heterosexual contact or through injecting 
drug use (IDU) - receiving HAART in a representative sample of hospitals with HIV care 
services. 
Our findings underline several issues that require further investigation. First, treatment 
for anxiety and mood disorders in France, which is often managed in primary care, 
leaves much to be desired in the context of the country’s HIV population. Though it has 
already been shown that integrating mental health services into HIV primary care is 
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necessary in order to help vulnerable populations manage HIV infection and 
precariousness, screening for anxiety disorders as well as their management in primary 
care may present many weaknesses (Weisberg, Dyck, Culpepper, & Keller, 2007). 
Furthermore, time of disclosure should be considered as a special step in the course of 
HIV infection. More than improving screening for psychiatric symptoms and adapting 
care to deal with anxiety symptoms, it is important to implement specific follow-up 
procedures at the time of HIV status disclosure. HIV infection still raises a lot of concern 
in terms of stigmatization and while waiting for this factor to be fully tackled in HIV 
prevention and follow-up care models, HIV infected persons need careful attention and 
adequate care through a patient-centered approach. 
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Table 1. Factors associated with regular benzodiazepine use* in HIV-infected individuals: Univariate 
analysis using logistic mixed models (VESPA survey, N=2265 patients) 
 
   Univariate analysis  
 
No. of years/  
No. of patients 
OR  
(95% CI) 
p-value 
 
Regular  
BZD use 
Non regular  
BZD use 
  
Age (Median [IQR])
µ
 42 [38 - 48] 42 [36 – 47] 1.01 [1-1.02] 0.06 
Female gender 107 (30) 497 (26) 1.22 [0.95-1.56] 0.12 
Living in a couple 42 (12) 458 (24) 0.43 [0.30-0.60] <0.001 
Secondary school certificate 104 (29) 636 (33) 0.83 [0.65-1.06] 0.13 
Employed 169 (47) 1173 (61) 0.57 [0.45-0.71] <0.001 
Migrant
$
 37 (11) 329 (17) 0.57 [0.40-0.81] 0.002 
History of discrimination 184 (52) 710 (37) 1.79 [1.43-2.25] <0.001 
HIV transmission group 
Heterosexuals 
MSM 
IDUs 
 
86 (24) 
159 (45) 
96 (27) 
 
676 (35) 
844 (44) 
281 (15) 
 
1 
1.49 [1.13-1.98] 
2.69 [1.95-3.71] 
 
 
0.005 
<0.001 
Anxiety symptoms
£
 
not clinically anxious 
borderline anxious 
clinically anxious 
 
71 (20) 
85 (24) 
200 (56) 
 
971 (50) 
471 (25) 
467 (25) 
 
1 
2.48 [1.77-3.46] 
5.85 [4.37-7.84] 
 
 
<0.001 
<0.001 
Depression symptoms
£
 
not clinically depressive 
borderline depressive 
clinically depressive 
 
215 (61) 
60 (17) 
74 (21) 
 
1522 (80) 
221 (12) 
142 (7) 
 
1 
1.94 [1.41-2.66] 
3.69 [2.69-5.05] 
 
 
<0.001 
<0.001 
Suicide attempts
§
 123 (35) 384 (20) 2.09 [1.63-2.67] <0.001 
Number of years since HIV diagnosis
1
 11 [7 – 15] 9 [5 – 14] 1.06 [1.04-1.08] <0.001 
Antidepressants
¤
 97 (27) 119 (6) 5.62 [4.17-7.58] <0.001 
Antiretroviral treatment 273 (77) 1536 (80) 0.80 [0.61-1.05] 0.10 
Undetectable viral load 240 (67) 1291 (68) 0.99 [0.78-1.26] 0.93 
HIV clinical stage 
Stage A or B 
Stage C 
 
253 (71) 
103 (29) 
 
1517 (79) 
393 (21) 
 
1 
1.56 [1.21-2.02] 
 
 
0.001 
HIV status disclosure 339 (95) 1672 (88) 2.77 [1.68-4.59] <0.001 
Self perceived side-effects 114 (32) 420 (22) 1.89 [1.45-2.47] <0.001 
Alcohol abuse (CAGE) 66 (19) 235 (12) 1.62 [1.20-2.19] 0.002 
 
* 
Regular benzodiazepine use was found in 356 (16%) patients 
µ
 per one year increase 
$ 
born outside France 
& 
5% of missing data 
£ 
using HADS and scoring in 3 categories, from 0 to 7 (not clinically anxious or depressive), from 8 to 10 
(borderline anxious or depressive) and more than 11 (clinically anxious or depressive) 
§ 
during lifetime 
¤ 
during the previous 4 weeks, in a medical or non-medical context 
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Table 2. Predictive factors of regular BDZ use in multivariate analyses using logistic models (n=2138) 
 Multivariate analysis 
 
Variable 
aOR (95% CI) 
p- 
value 
Age 1.03 [1.01-1.04] 0.001 
Living in a couple
 
0.45 [0.31-0.66] <0.001 
HIV clinical stage C (versus A or B) 1.51 [1.14-2.01] 0.004 
HIV transmission group 
Heterosexuals 
MSM 
IDUs 
 
1 
1.35 [0.99-1.84] 
2.13 [1.50-3.03] 
 
 
0.06 
<0.001 
Migrant 0.64 [0.42-0.98] 0.04 
Suicide attempts
§
 1.56 [1.18-2.05] 0.002 
HIV status disclosure 1.78 [1.02-3.09] 0.04 
Anxiety symptoms
£
 
not clinically anxious 
borderline anxious 
clinically anxious 
 
1 
2.43 [1.71-3.45] 
6.02 [4.39-8.26] 
 
 
<0.001 
<0.001 
§ 
during lifetime 
£ 
using HAD scale and scoring in 3 categories, from 0 to 7 (not clinically anxious), from 8 to 10 (borderline 
anxious) and more than 11 (clinically anxious) 
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